A record of what Nagaraj Shetti said publicly, with the source. Not advice.
“Glenmark Pharmaceuticals is primed for a breakout, currently consolidating after a good recovery and sitting at the edge of breaking out of its range with a constructive broader chart pattern. He recommends buying at Rs 2,205, targeting Rs 2,310, with a stop loss at Rs 2,150.”
Nagaraj Shetti’s track record (trackable calls only): 139 graded calls · 95% CI 34–50%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.
Entry: ₹2,205, as stated.
Target ₹2,310, stop ₹2,150, as stated.
No time frame is stated, so it is tracked until a close reaches ₹2,310 or ₹2,150: there is no fixed window.
The target ₹2,310 was reached on a close before the stop ₹2,150. Hit.
The grader’s working: R3 TRADE_SETUP: entered ₹2205 on 2026-04-15 (stated entry ₹2205, LEVEL_CMP entry, filled); target ₹2310 reached at close ₹2335 on 2026-04-23. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open.
How it played out
How this is worked out- Target or stop first
- The target was reached on a close before the stop was.
- Time to target
- The target was reached on a close 6 trading sessions (8 calendar days) after the entry.
- Worst close against it
- No close was ever against the call before the target was reached. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.